Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06376968

Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:

• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.

A crossover design is used to compare treatments with or without the BioLogic Fusion function activated.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione

Bologna, Emilia-Romagna, 40138, Italy

Location status: Recruiting

Location contact

Annalisa Zucchelli, Prof.

CONTACT

Annalisa Zucchelli, Prof.

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female subjects ≥18 years of age
  • Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months
  • Dialysis frequency 3 x per week
  • Dialysis duration per session ≥ 4h
  • Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes
  • No residual renal function (definition: ≤100 ml urine/day) - changed to "No to minimal residual renal function (definition: ≤ 300 ml/day)" with Amendment 1 (CIP version 6)
  • Stable dry body weight for at least 4 weeks
  • Subjects who are willing to give a voluntary consent to participate in the study

Exclusion criteria

  • Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
  • Vascular access insufficiency (mean blood flow <200ml/min)
  • Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile - changed to: " Patients treated with dialysis profiles during the 9 prescreening visits: sodium profile, UF profile, and temperature profile. However, patients on sodium, ultrafiltration or temperature profiling expected to reduce intradialytic hypotensive episodes can be evaluated for enrollment when their frequency of sessions complicated by hypotension demonstrate the lack of efficacy of the applied profiles" with Amendment 1 (CIP version 6)
  • Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)
  • Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period
  • Factors which may interfere with full participation in the trial
  • Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)
  • Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study

Treatment and study plan

BioLogic Fusion

Device

Dialysis conducted with Dialog iQ dialysis machine either using the BioLogic Fusion option or not using it. This is only a biologic feedback system using blood pressure and residual blood volume as parameters to predict potential hypotensive episodes. If switched off, standard dialysis treatment happens, if switched on, the system tries to predict and prevent hypotensive episodes.

Primary outcomes

  1. Post-dialysis body weight

    Time frame: 12 weeks

    percentage of sessions with reached prescribed post-dialysis body weight

Study contacts

Contact information is provided by the study sponsor or research team.

Seebode Christina, Dr.

CONTACT

[email protected]

Strube Frank

CONTACT

[email protected]

+4915257240618

Sponsors and collaborators

Lead sponsor

B.Braun Avitum AG

Industry

Registry information

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Apr 22, 2024
Registry last updated
Sep 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.